Connect Biopharma Holdings (CNTB) Treasury Shares (2020 - 2026)
Connect Biopharma Holdings' (CNTB) quarterly Treasury Shares came in at $180000.0 in Q2 2026, little changed year-over-year from $180000.0 in Q2 2025, and little changed quarter-over-quarter from $180000.0 in Q1 2026.
Analysis
Connect Biopharma Holdings (CNTB) Treasury Shares (2020 - 2026) Analysis & Trends
Connect Biopharma Holdings has disclosed Treasury Shares across 7 years of filings, most recently posting $180000.0 for Q2 2026.
- In Q2 2026, Treasury Shares changed 0.0% year-over-year to $180000.0; the TTM figure through Jun 2026 stood at $180000.0 (changed 0.0% YoY), while the FY2025 annual figure was $180000.0, changed 0.0% from the prior year.
- Treasury Shares came in at $180000.0 for Q2 2026 at Connect Biopharma Holdings, roughly flat from $180000.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $2.5 million in Q4 2024 to a low of $2.1 million in Q4 2025.
- Average Treasury Shares over 3 years is $2.4 million, with a median of $2.4 million recorded in 2023.
- Year-over-year, Treasury Shares declined 10.11% in 2022 and rose 11.8% in 2024.
- Over 5 years, Treasury Shares stood at $163663.1 in 2022, then grew by 9.98% to $180000.0 in 2023, then changed by 0.0% to $180000.0 in 2024, then changed by 0.0% to $180000.0 in 2025, then changed by 0.0% to $180000.0 in 2026.
- Per Business Quant data, the three most recent Treasury Shares figures were $180000.0 in Q2 2026, $180000.0 in Q1 2026, and $180000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 36.40 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.80 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Connect Biopharma Holdings | 129.86 Mn | 129.86 Mn | - | 180,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 180,000.00 |
| Jun 30, 2026 | 180,000.00 |
| Mar 31, 2026 | 180,000.00 |
| Mar 31, 2026 | 180,000.00 |
| Dec 31, 2025 | 180,000.00 |
| Dec 31, 2025 | 180,000.00 |
| Dec 31, 2025 | 2.15 Mn |
| Dec 31, 2025 | 2.15 Mn |
| Sep 30, 2025 | 180,000.00 |
| Sep 30, 2025 | 180,000.00 |
| Jun 30, 2025 | 180,000.00 |
| Jun 30, 2025 | 180,000.00 |
| Mar 31, 2025 | 180,000.00 |
| Mar 31, 2025 | 180,000.00 |
| Dec 31, 2024 | 2.51 Mn |
| Dec 31, 2024 | 180,000.00 |
| Dec 31, 2024 | 2.51 Mn |
| Dec 31, 2024 | 180,000.00 |
| Jun 30, 2024 | 180,000.00 |
| Jun 30, 2024 | 180,000.00 |